Daehan Pharmaceutical

023910 · KOSDAQ · ₩023910 · 대한약품

₩24,900▼ ₩300 (1.19%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩89,401

vs the current price (₩24,900)

Enterprise value
₩477B
Equity value
₩536B
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 259% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • To match today's price of ₩24,900, the model needs an operating margin of 4.8% every year (it uses 17.0%).
  • Today's P/E is 5.3× against a typical 6.2× over the last 10 years.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
₩61,232
+145.9%
Base
₩89,401
+259.0%
Bull
₩136,020
+446.3%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (17.0%).

Revenue growth

  • 4.2%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.2% a year, annual reports), fading to 3% by year 5.

  • 3.9%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.2% a year, annual reports), fading to 3% by year 5.

  • 3.6%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.2% a year, annual reports), fading to 3% by year 5.

  • 3.3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.2% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (4.2% a year, annual reports), fading to 3% by year 5.

Business

  • 17%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 7.9%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 9.9%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 17.1%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.11%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-28.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.61%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩217B
Net debt (borrowings and leases − cash and deposits)
−₩60B
Shares
6,000,000
Share price
₩24,900
Market cap
₩149B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩196B₩204B₩209B₩226B₩234B₩243B₩251B₩258B
Growth6.3%4.2%2.2%4.2%3.9%3.6%3.3%3.0%
EBIT₩36B₩38B₩31B₩38B₩40B₩41B₩43B₩44B
EBIT margin18.3%18.6%14.9%17.0%17.0%17.0%17.0%17.0%
After-tax EBIT₩26B₩28B₩23B₩28B₩29B₩30B₩31B₩32B
+ Depreciation———₩18B₩19B₩19B₩20B₩20B
− Capital spending—₩16B₩25B₩22B₩23B₩24B₩25B₩26B
− Working capital−₩7.7B₩382M₩54B₩1.6B₩1.5B₩1.4B₩1.4B₩1.3B
Free cash flow———₩22B₩23B₩24B₩25B₩25B
Discount factor———0.9310.8670.8070.7510.700
Present value———₩20B₩20B₩19B₩18B₩18B

Terminal value ₩546B, worth ₩382B today: 80% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩51,345 a share)Now 0.48×₩28,1840.55×₩35,0210.68×₩42,5000.83×
Price / earnings (last 12 months: ₩4,699 a share)Now 5.30×₩24,5105.22×₩28,9086.15×₩36,1907.70×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩93,244₩99,878₩108,011₩118,218₩131,411
6.9%₩85,928₩91,297₩97,754₩105,671₩115,606
7.4%₩79,760₩84,174₩89,401₩95,686₩103,392
7.9%₩74,490₩78,169₩82,466₩87,554₩93,672
8.4%₩69,936₩73,038₩76,619₩80,802₩85,755

Now (TTM)

Market cap
₩149B
Enterprise value
₩90B
P/E
5.3×
P/B
0.5×
P/S
0.7×
EV/EBITDA
—
Dividend yield
4.0%

Over time (at each year end)

20252024202320222021
Price₩29,250₩26,200₩27,750₩30,600₩28,700
Market cap₩176B₩157B₩167B₩184B₩172B
P/E6.3×4.7×5.9×7.4×7.6×
P/B0.6×0.6×0.7×0.8×0.8×
P/S0.8×0.8×0.8×1.0×1.0×
EV/EBITDA—————
Dividend yield3.4%3.4%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Daehan Pharmaceutical5.3×0.5×0.7×—4.0%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Daehan Pharmaceutical / 대한약품 / 023910 / KRX:023910

Source: KRX statistical information